vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $44.9M, roughly 1.1× AbCellera Biologics Inc.). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -19.9%, a 14.8% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -14.2%). READING INTERNATIONAL INC produced more free cash flow last quarter ($4.1M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 5.6%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
ABCL vs RDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $50.3M |
| Net Profit | $-8.9M | $-2.6M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | -1.9% |
| Net Margin | -19.9% | -5.1% |
| Revenue YoY | 788.4% | -14.2% |
| Net Profit YoY | 73.9% | -14.5% |
| EPS (diluted) | $-0.03 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $50.3M | ||
| Q3 25 | $9.0M | $52.2M | ||
| Q2 25 | $17.1M | $60.4M | ||
| Q1 25 | $4.2M | $40.2M | ||
| Q4 24 | $5.0M | $58.6M | ||
| Q3 24 | $6.5M | $60.1M | ||
| Q2 24 | $7.3M | $46.8M | ||
| Q1 24 | $10.0M | $45.1M |
| Q4 25 | $-8.9M | $-2.6M | ||
| Q3 25 | $-57.1M | $-4.2M | ||
| Q2 25 | $-34.7M | $-2.7M | ||
| Q1 25 | $-45.6M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-51.1M | $-7.0M | ||
| Q2 24 | $-36.9M | $-12.8M | ||
| Q1 24 | $-40.6M | $-13.2M |
| Q4 25 | -63.7% | -1.9% | ||
| Q3 25 | -851.8% | -0.6% | ||
| Q2 25 | -290.2% | 4.8% | ||
| Q1 25 | -1479.6% | -17.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -1439.4% | -0.6% | ||
| Q2 24 | -1276.2% | -16.4% | ||
| Q1 24 | -551.5% | -16.7% |
| Q4 25 | -19.9% | -5.1% | ||
| Q3 25 | -637.8% | -8.0% | ||
| Q2 25 | -203.3% | -4.4% | ||
| Q1 25 | -1077.2% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -785.4% | -11.7% | ||
| Q2 24 | -504.3% | -27.4% | ||
| Q1 24 | -408.0% | -29.4% |
| Q4 25 | $-0.03 | $-0.11 | ||
| Q3 25 | $-0.19 | $-0.18 | ||
| Q2 25 | $-0.12 | $-0.12 | ||
| Q1 25 | $-0.15 | $-0.21 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | $-0.17 | $-0.31 | ||
| Q2 24 | $-0.13 | $-0.57 | ||
| Q1 24 | $-0.14 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $966.9M | $-18.2M |
| Total Assets | $1.4B | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $10.5M | ||
| Q3 25 | $83.2M | $8.1M | ||
| Q2 25 | $92.4M | $9.1M | ||
| Q1 25 | $159.3M | $5.9M | ||
| Q4 24 | $156.3M | $12.4M | ||
| Q3 24 | $126.6M | $10.1M | ||
| Q2 24 | $148.3M | $9.3M | ||
| Q1 24 | $123.6M | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $966.9M | $-18.2M | ||
| Q3 25 | $964.0M | $-12.1M | ||
| Q2 25 | $1.0B | $-7.7M | ||
| Q1 25 | $1.0B | $-8.1M | ||
| Q4 24 | $1.1B | $-4.4M | ||
| Q3 24 | $1.1B | $1.6M | ||
| Q2 24 | $1.1B | $6.5M | ||
| Q1 24 | $1.1B | $18.0M |
| Q4 25 | $1.4B | $434.9M | ||
| Q3 25 | $1.4B | $435.2M | ||
| Q2 25 | $1.4B | $438.1M | ||
| Q1 25 | $1.3B | $441.0M | ||
| Q4 24 | $1.4B | $471.0M | ||
| Q3 24 | $1.4B | $495.7M | ||
| Q2 24 | $1.4B | $494.9M | ||
| Q1 24 | $1.5B | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $4.3M |
| Free Cash FlowOCF − Capex | $-44.6M | $4.1M |
| FCF MarginFCF / Revenue | -99.4% | 8.2% |
| Capex IntensityCapex / Revenue | 21.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $4.3M | ||
| Q3 25 | $-52.6M | $295.0K | ||
| Q2 25 | $-32.4M | $1.6M | ||
| Q1 25 | $-11.6M | $-7.7M | ||
| Q4 24 | $-108.6M | $8.0M | ||
| Q3 24 | $-28.9M | $1.3M | ||
| Q2 24 | $-30.0M | $-10.4M | ||
| Q1 24 | $-41.7M | $-2.8M |
| Q4 25 | $-44.6M | $4.1M | ||
| Q3 25 | $-61.5M | $-246.0K | ||
| Q2 25 | $-45.8M | $1.2M | ||
| Q1 25 | $-22.2M | $-8.0M | ||
| Q4 24 | $-187.0M | $7.0M | ||
| Q3 24 | $-47.4M | $-1.1M | ||
| Q2 24 | $-50.1M | $-10.6M | ||
| Q1 24 | $-65.8M | $-4.7M |
| Q4 25 | -99.4% | 8.2% | ||
| Q3 25 | -687.0% | -0.5% | ||
| Q2 25 | -267.9% | 1.9% | ||
| Q1 25 | -524.0% | -19.8% | ||
| Q4 24 | -3702.8% | 12.0% | ||
| Q3 24 | -728.4% | -1.8% | ||
| Q2 24 | -683.8% | -22.7% | ||
| Q1 24 | -661.5% | -10.4% |
| Q4 25 | 21.9% | 0.3% | ||
| Q3 25 | 99.7% | 1.0% | ||
| Q2 25 | 78.2% | 0.6% | ||
| Q1 25 | 251.1% | 0.6% | ||
| Q4 24 | 1552.7% | 1.7% | ||
| Q3 24 | 284.6% | 4.0% | ||
| Q2 24 | 274.6% | 0.5% | ||
| Q1 24 | 242.5% | 4.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
